DDInter393 DDInter927
Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Clarithromycin {u} (Compound) resembles {v} (Compound) Troleandomycin
Clarithromycin {u} (Compound) resembles {v} (Compound) Josamycin
Clarithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Azithromycin
Clarithromycin {u} (Compound) binds {v} (Gene) ABCB1
Clarithromycin {u} (Compound) upregulates {v} (Gene) SLC25A14
Clarithromycin {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Clarithromycin {u} (Compound) downregulates {v} (Gene) TIMM9
Clarithromycin {u} (Compound) causes {v} (Side Effect) Gingival bleeding
Clarithromycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amoxicillin
Clarithromycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cannabidiol
Clarithromycin (Compound) resembles Troleandomycin (Compound)
Clarithromycin (Compound) resembles Josamycin (Compound)
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin
Clarithromycin (Compound) binds ABCB1 (Gene)
Clarithromycin (Compound) upregulates SLC25A14 (Gene)
Clarithromycin (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class)
Clarithromycin (Compound) downregulates TIMM9 (Gene)
Clarithromycin (Compound) causes Gingival bleeding (Side Effect)
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Amoxicillin
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Cannabidiol